BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21518948)

  • 1. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
    De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
    Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma.
    Jacobs IA; Chang CK; Salti GI
    Am Surg; 2004 Jan; 70(1):59-62. PubMed ID: 14964550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
    Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
    Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
    Nahabedian MY; Tufaro AP; Manson PN
    Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy.
    Zapas JL; Coley HC; Beam SL; Brown SD; Jablonski KA; Elias EG
    J Am Coll Surg; 2003 Sep; 197(3):403-7. PubMed ID: 12946795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?
    Carpenter S; Pockaj B; Dueck A; Gray R; Kurtz D; Sekulic A; Casey W
    Am J Surg; 2008 Dec; 196(6):834-42; discussion 842-3. PubMed ID: 19095097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-adrenergic-blocking drugs and melanoma: current state of the art.
    De Giorgi V; Grazzini M; Gandini S; Benemei S; Asbury CD; Marchionni N; Geppetti P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1461-7. PubMed ID: 23249110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
    Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
    Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
    Keijzer R; Bril H; van der Loo EM; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients.
    Leong SP; Accortt NA; Essner R; Ross M; Gershenwald JE; Pockaj B; Hoekstra HJ; Garberoglio C; White RL; Chu D; Biel M; Charney K; Wanebo H; Avisar E; Vetto J; Soong SJ;
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):370-3. PubMed ID: 16618904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
    Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
    Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
    Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
    Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
    J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.